Legacy Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Legacy Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-118	Closed	-$10K	–	356
2017 Q3	$10K	Buy	+118	New	+$10.4K	0.01%	217

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legacy Advisors's BMRN Position: Q4 2017 in Review

Legacy Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 118 shares — an estimated $10K sold.

Legacy Advisors first reported a position in BMRN in Q3 2017 and held it in 1 quarter. The position peaked at $10K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Legacy Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Legacy Advisors sold 118 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $10K.
Legacy Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 1 quarter.
Legacy Advisors's BioMarin Pharmaceuticals position peaked at $10K in Q3 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Legacy Advisors's 13F filing for Q4 2017, filed 26 Jan 2018.